ReviewFrontiers in immunology2026
The central regulator HIF-1α in digestive system pathologies: inflammation and cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling role of arginine-NO metabolism by targeting HIF-1α signaling in mediating esophageal squamous cell carcinoma.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia-inducible factor-1α (HIF-1α) is a critical transcriptional regulator that allows cells to detect and respond to hypoxic conditions. Its stabilized expression and prolonged activation significantly contribute to the development and progression of inflammatory diseases and malignancies within the digestive system. In the context of inflammation, HIF-1α plays a pivotal role in the pathogenesis of various disorders-including periodontitis, eosinophilic esophagitis, viral hepatitis, pancreatitis, and inflammatory bowel disease-by modulating the expression of inflammatory mediators, driving cellular metabolic reprogramming, and influencing tissue barrier function. In terms of tumor biology, this review synthesizes pan-cancer analysis data to summarize the expression patterns of HIF-1α in major gastrointestinal malignancies, including esophageal, gastric, pancreatic, hepatocellular, and colorectal cancers. It elucidates HIF-1α's role in directly promoting tumor cell proliferation, invasion, and drug resistance, while also remodeling the tumor microenvironment to regulate immune responses. We dissect how HIF-1α cooperatively drives the formation of an immunosuppressive microenvironment, thereby influencing the efficacy of immunotherapy. This review aims to integrate the regulatory networks and molecular mechanisms of HIF-1α in digestive system inflammation, tumors, and their immune microenvironment, ultimately providing novel theoretical foundations and strategic insights for targeted therapies and immune interventions in related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.